8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 17, 2021

GOSSAMER BIO, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware	001-38796	47-5461709
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

3013 Science Park Road

San Diego, California, 92121

(Address of Principal Executive Offices) (Zip Code)

(858) 684-1300

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	GOSS	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 17, 2021, Luisa Salter-Cid, Ph.D., resigned from her position as the Chief Scientific Officer of the Company effective as of April 30, 2021.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit Number	Description
99.1	Press Release dated April 20, 2021

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	GOSSAMER BIO, INC.
Date: April 20, 2021	By:	/s/ Christian Waage
		Christian Waage
		Executive Vice President & General Counsel

2

EX-99.1

Exhibit 99.1

Gossamer Bio Announces Executive Management Transition and Promotion of Laura Carter, Ph.D., to Chief Scientific Officer

SAN DIEGO — (BUSINESS WIRE) — April 20, 2021 — Gossamer Bio, Inc.(Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Luisa Salter-Cid, Ph.D., Gossamer’s Chief Scientific Officer, is resigning from Gossamer effective April 30, 2021. On that date, Laura Carter, Ph.D., currently Gossamer’s Senior Vice President, Research & Translational Biology, will be promoted to Chief Scientific Officer.

“I would like to thank Luisa for her many contributions to Gossamer Bio,” said Faheem Hasnain, Chairman, President and CEO of Gossamer Bio. “Luisa has assembled a world-class research team that has made significant progress in developing our pre-clinical pipeline, and we wish her the best of luck as she moves on to new endeavors.”

Dr. Salter-Cid has served as Chief Scientific Officer since joining Gossamer in September 2018 following a distinguished career at Bristol Myers Squibb.

“I am tremendously excited to welcome Laura Carter to the executive management team,” said Mr. Hasnain. “Laura is a brilliantly talented immunologist and a proven leader, and I look forward to working together even more closely to develop the next generation of clinical programs for Gossamer.”

Dr. Carter has over 20 years of industry experience spanning target identification and validation activities through Phase 2 clinical trials in multiple therapeutic areas. Prior to joining Gossamer in 2019, she was Senior Vice President, Biology at Lycera Corporation, where she led the development of several immunology and immuno-oncology clinical product candidates. Before joining Lycera, she was a scientific director in the respiratory, inflammation and autoimmunity group at MedImmune, where she was responsible for overseeing research and development of treatments for autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis. Prior to MedImmune, she was a senior research investigator in the inflammation biology and translational science department at Array Biopharma. She started her career in industry at Wyeth, where, among other accomplishments, her basic science studies were critical in identifying and characterizing the negative regulatory role of PD-1:PD-L interactions on T cell function in vitro and in vivo.

Dr. Carter received an S.B. in biological science from Massachusetts Institute of Technology and a Ph.D. in molecular pathology from the University of California, San Diego School of Medicine.

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

For Investors and Media:

Bryan Giraudo, Chief Financial Officer

Gossamer Bio Investor Relations

ir@gossamerbio.com

XML

Cover	Apr. 17, 2021
Cover [Abstract]
Document Type	8-K
Document Period End Date	Apr. 17, 2021
Entity Registrant Name	GOSSAMER BIO, INC.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-38796
Entity Tax Identification Number	47-5461709
Entity Address, Address Line One	3013 Science Park Road
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	684-1300
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	GOSS
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Central Index Key	0001728117
Amendment Flag	false